847 related articles for article (PubMed ID: 28810803)
41. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.
Zhang Q; Li H; Yang J; Li L; Zhang B; Li J; Zheng J
Curr Gene Ther; 2013 Feb; 13(1):65-70. PubMed ID: 23256743
[TBL] [Abstract][Full Text] [Related]
42. Considerations for Clinical Review of Cellular Therapy Products: Perspectives of the China Food and Drug Administration Center for Drug Evaluation.
Liu Y; Zhao C; Gao L; Yang H; He R; Gao C
Hum Gene Ther; 2018 Feb; 29(2):121-127. PubMed ID: 29446998
[TBL] [Abstract][Full Text] [Related]
43. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
44. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Magee MS; Snook AE
Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
[TBL] [Abstract][Full Text] [Related]
45. CAR T cells for solid tumors: armed and ready to go?
Kakarla S; Gottschalk S
Cancer J; 2014; 20(2):151-5. PubMed ID: 24667962
[TBL] [Abstract][Full Text] [Related]
46. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.
Wang L; Zhang L; Dunmall LC; Wang YY; Fan Z; Cheng Z; Wang Y
Cancer Lett; 2024 Jun; 591():216871. PubMed ID: 38604310
[TBL] [Abstract][Full Text] [Related]
47. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
48. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
Harris DT; Kranz DM
Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086
[TBL] [Abstract][Full Text] [Related]
49. Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?
Hombach AA; Abken H
Expert Rev Clin Immunol; 2017 Feb; 13(2):151-155. PubMed ID: 27546707
[TBL] [Abstract][Full Text] [Related]
50. [Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review].
Fang Z; Han H; Liang L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):944-948. PubMed ID: 31814572
[TBL] [Abstract][Full Text] [Related]
51. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
[TBL] [Abstract][Full Text] [Related]
52. [Research Progress on Chimeric Antigen Receptor T Cells-Review].
Zhuang RM; Cheng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1829-1832. PubMed ID: 29262925
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
Gross G; Eshhar Z
Annu Rev Pharmacol Toxicol; 2016; 56():59-83. PubMed ID: 26738472
[TBL] [Abstract][Full Text] [Related]
54. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
[TBL] [Abstract][Full Text] [Related]
55. Chimeric antigen receptor-modified T cells strike back.
Frigault MJ; Maus MV
Int Immunol; 2016 Jul; 28(7):355-63. PubMed ID: 27021308
[TBL] [Abstract][Full Text] [Related]
56. Exploiting natural killer group 2D receptors for CAR T-cell therapy.
Demoulin B; Cook WJ; Murad J; Graber DJ; Sentman ML; Lonez C; Gilham DE; Sentman CL; Agaugue S
Future Oncol; 2017 Aug; 13(18):1593-1605. PubMed ID: 28613086
[TBL] [Abstract][Full Text] [Related]
57. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.
Jin C; Yu D; Essand M
Immunotherapy; 2016 Dec; 8(12):1355-1361. PubMed ID: 28000533
[TBL] [Abstract][Full Text] [Related]
58. Targeting the tumor and its associated stroma: One and one can make three in adoptive T cell therapy of solid tumors.
Mondino A; Vella G; Icardi L
Cytokine Growth Factor Rev; 2017 Aug; 36():57-65. PubMed ID: 28629762
[TBL] [Abstract][Full Text] [Related]
59. CAR T Cell Therapy: A Game Changer in Cancer Treatment.
Almåsbak H; Aarvak T; Vemuri MC
J Immunol Res; 2016; 2016():5474602. PubMed ID: 27298832
[TBL] [Abstract][Full Text] [Related]
60. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]